DART (19-14434) Durvalumab (MEDI4736) After chemoRadioTherapy (DART) for NSCLC patients – a phase II translational and biomarker study investigating PDL1 positive and negative patients

Status

Recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502640-12-01

Acronym

ESR-19-14434

Enrollment

130

Registered

2024-09-27

Start date

2024-09-27

Completion date

Unknown

Last updated

2024-10-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer (NSCLC)

None listed

Sex/Gender

All

Age

18 Years to No maximum

Estonia, Finland, Lithuania, Norway

None listed

Source: EU CTIS · Data processed: Feb 4, 2026